Clene Nanomedicine
Manufacturing · Utah, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
6550 S Millrock Dr Ste G50, Salt Lake Ci...Phone Number
(801) 676-9695Website
www.clene.comRevenue
<$5 MillionStock Symbol
CLNNIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About Clene Nanomedicine
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectiousRead more
Clene Nanomedicine Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Clene Nanomedicine your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Clene Nanomedicine has recently received funding, and reach out quickly before it becomes old news!
Check out if Clene Nanomedicine is spiking on competitors!
Earning: See what the market has to say on Clene Nanomedicine recently announced quarterly report
Funding: Get notified immidiatlly once Clene Nanomedicine has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Clene Nanomedicine had a recent Job posting/layoffs
Product Launch: Get notified when Clene Nanomedicine launches new products
Congratulate Masked Content for being promoted to Masked Content at Clene Nanomedicine
Clene Nanomedicine, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Clene Nanomedicine
Compare insights from companies similar to Clene Nanomedicine, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Clene Nanomedicine is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Clene Nanomedicine is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Clene Nanomedicine.
Clene Nanomedicine financials insights
Gather financial insights about Clene Nanomedicine, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$31.6M
2016
Series B
$17M
2020
Debt
$350K
Series D
$42.5M
2023
Other Financing Round
$40M
2024
Other Financing Round
$7.3M
2025
Stock/Share Issuance
$1.5M
Clene Nanomedicine Tech Stack
A closer look at the technologies used by Clene Nanomedicine
See more technologies
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
, according to a mid-level source in accounting, has completed initiatives related to project accounting within the last twelve months.
Accounting, Financial Reporting, Finance
Project
, according to a mid-level source in accounting, has completed initiatives related to benefits within the last twelve months.
Accounting, Compensation & Benefits, Financial Reporting, Finance
Project
, according to a mid-level source in accounting, is in the midst of initiatives related to technical accounting. The organization is currently evaluating various vendors.
Accounting, Financial Reporting, Finance
Project
Accounting, Audit, Financial Reporting, Internal Audit & Control, Finance
Clene Nanomedicine News & Media
Clene Announces $7 Million Underwritten Offering of Common Stock
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary, Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced the pricing of an underwritten registered direct offering of 1,000,000 shares of common stock at aClene to Present at Upcoming May Conferences
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in May.After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS
SALT LAKE CITY, May 04, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced receipt of final meeting minutes following its recent Type C meeting with the U.S. Food and Drug Administration (FDA).Clene Reports Full Year 2025 Financial Results and Recent Operating Highlights
SALT LAKE CITY, March 12, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced its full year 2025 financial results and provided recent updates on its CNM-Au8 p
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Clene Nanomedicine
Sign Up For FreeTo access detailed company insights
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au... Read More
